Arch Therapeutics, Inc.
ARTH · OTC
9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | |
|---|---|---|---|---|
| Revenue | $76 | $16 | $12 | $0 |
| % Growth | 383.8% | 35.3% | – | – |
| Cost of Goods Sold | $78 | $51 | $26 | $7 |
| Gross Profit | -$2 | -$36 | -$15 | -$7 |
| % Margin | -3.2% | -229% | -127.3% | – |
| R&D Expenses | $671 | $1,153 | $1,353 | $1,611 |
| G&A Expenses | $4,371 | $4,520 | $5,009 | $3,760 |
| SG&A Expenses | $4,371 | $4,520 | $5,009 | $3,760 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $5,042 | $5,673 | $6,362 | $5,371 |
| Operating Income | -$5,044 | -$5,709 | -$6,377 | -$5,371 |
| % Margin | -6,661.7% | -36,473.3% | -55,141.6% | – |
| Other Income/Exp. Net | -$1,938 | $433 | $137 | $661 |
| Pre-Tax Income | -$6,983 | -$5,276 | -$6,240 | -$4,691 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$6,983 | -$4,276 | -$6,569 | -$4,012 |
| % Margin | -9,221.4% | -27,318.3% | -56,802.8% | – |
| EPS | -2.27 | -3.56 | -5.97 | -4.27 |
| % Growth | 36.2% | 40.4% | -39.8% | – |
| EPS Diluted | -2.27 | -3.56 | -5.97 | -4.27 |
| Weighted Avg Shares Out | 3,074 | 1,200 | 1,100 | 940 |
| Weighted Avg Shares Out Dil | 3,074 | 1,200 | 1,100 | 940 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $19 |
| Interest Expense | $3,097 | $567 | $151 | $18 |
| Depreciation & Amortization | $2 | $3 | $3 | $7 |
| EBITDA | -$3,884 | -$4,706 | -$6,087 | -$5,345 |
| % Margin | -5,129.6% | -30,064% | -52,636.1% | – |